Skip to main content
. 2015 Jun 10;107(9):djv159. doi: 10.1093/jnci/djv159

Figure 3.

Figure 3.

Absolute number of newly diagnosed invasive and in situ estrogen receptor (ER)–positive (ER+) and ER-negative (ER-) breast cancers in the United States by single year of age, 2011 and 2030. In each panel, 2011 forecast is shown in red and 2030 in blue; error bars for 2011 and shaded bands for 2030 show point-wise 95% confidence limits. A) ER+ invasive, (B) ER+ in situ, (C) ER- invasive, (D) ER- in situ. ER = estrogen receptor.